For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...